Shenzhen Capital Group Co-Leads $62M Round In Chinese Biopharmaceutical Firm Zelgen

Login to View

Shenzhen Capital Group Co., Ltd, Minsheng Life Insurance and Share Capital have led a RMB400 million (US$62 million) series B round in Suzhou Zelgen Biosciences Co., Ltd., a Chinese biopharmaceutical company.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in

China Money Network Subscription